Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Core Viewpoint - Jasper Therapeutics is hosting a webinar to discuss findings from the BEACON study and preliminary data from the ETESIAN study, focusing on briquilimab's potential in treating mast cell driven diseases [1][2] Group 1: Company Overview - Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, an antibody therapy targeting c-Kit (CD117) for chronic mast cell diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [3] - Briquilimab works by blocking stem cell factor from binding to the KIT receptor, leading to mast cell depletion and reducing inflammation associated with these diseases [3] - The company has demonstrated efficacy and safety of briquilimab in clinical studies involving patients and healthy volunteers, showing positive outcomes in CSU and CIndU [3] Group 2: Webinar Details - The webinar is scheduled for Tuesday, December 2, 2025, at 8:00 am ET, featuring presentations from Jasper management and Dr. Martin Metz, a leading investigator in the BEACON study [1][2] - A live Q&A session will follow the formal presentation, allowing for direct engagement with the audience [1]